Crescent-, Viridian-backed Fusion Antibodies to list on AIM
Fusion Antibodies, a UK-based biotechnology company backed by Viridian Growth Fund and Crescent Capital, has announced its intention to float on the AIM segment of the London stock exchange.
More on Exits
Lenders sway fate of auctions in volatile LBO market
Vendors increasingly sounding out lenders before bidders to navigate uncertain M&A landscape
Nordic picks Jefferies for upcoming Sunrise Medical auction
German wheelchair specialist was acquired in 2015 and moved to a continuation fund in 2018
GP Profile: Inspirit anticipates carve-outs uptick with fundraising on the horizon by year-end
Complex carve-outs specialist could raise around GBP 75m for its second fund with debut vehicle around 70% deployed
AnaCap exits Oona Health in EUR 302m sale to Topdanmark
Deal for Danish health insurance provider generates a 4x money multiple and 40% IRR
Latest News
Great Hill opens London office to expand activity in Europe
Managing director Drew Loucks will head Boston-based PE firm’s new arm
The Bolt-Ons Digest – 20 March 2023
Unquote’s selection of the latest add-ons with Cinven's ETC, PAI's Apleona, TA Associate's Fairstone, and more
Lenders sway fate of auctions in volatile LBO market
Vendors increasingly sounding out lenders before bidders to navigate uncertain M&A landscape
Keyhaven eyes Q4 2023 fund launch amidst lower mid-market GP-leds boom
Secondaries firm looks ahead to fourth fund; sweet spot of EUR 50m-100m for deals but can go up to EUR 500m